First National Bank of Mount Dora Trust Investment Services Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

First National Bank of Mount Dora Trust Investment Services lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 28.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,336 shares of the biopharmaceutical company’s stock after acquiring an additional 961 shares during the quarter. First National Bank of Mount Dora Trust Investment Services’ holdings in Gilead Sciences were worth $318,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Walker Asset Management LLC boosted its stake in shares of Gilead Sciences by 3.6% during the 1st quarter. Walker Asset Management LLC now owns 4,763 shares of the biopharmaceutical company’s stock worth $349,000 after acquiring an additional 165 shares in the last quarter. Banque Cantonale Vaudoise lifted its stake in Gilead Sciences by 17.5% in the 1st quarter. Banque Cantonale Vaudoise now owns 127,866 shares of the biopharmaceutical company’s stock valued at $9,365,000 after buying an additional 19,030 shares in the last quarter. Bruce G. Allen Investments LLC lifted its stake in Gilead Sciences by 16.0% in the 1st quarter. Bruce G. Allen Investments LLC now owns 1,541 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 212 shares in the last quarter. Czech National Bank lifted its stake in Gilead Sciences by 0.4% in the 1st quarter. Czech National Bank now owns 219,235 shares of the biopharmaceutical company’s stock valued at $16,059,000 after buying an additional 962 shares in the last quarter. Finally, Fulton Bank N.A. lifted its stake in Gilead Sciences by 68.2% in the 1st quarter. Fulton Bank N.A. now owns 31,493 shares of the biopharmaceutical company’s stock valued at $2,307,000 after buying an additional 12,775 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.1 %

NASDAQ GILD traded up $1.42 during trading hours on Friday, hitting $69.91. The company had a trading volume of 12,425,932 shares, compared to its average volume of 7,456,776. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a market capitalization of $87.10 billion, a price-to-earnings ratio of 199.94, a P/E/G ratio of 1.27 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm’s 50 day moving average is $65.68 and its 200 day moving average is $73.03.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.37 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.41%. Gilead Sciences’s payout ratio is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on GILD shares. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Friday, June 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Morgan Stanley reduced their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research note on Wednesday, April 24th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $83.47.

Read Our Latest Analysis on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.